MedTrace Logo

Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease

NCT00584740 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2015-03-31

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and efficacy of AIN457 in patients with moderate to severe active Crohn's disease.

Conditions

Interventions

DRUG

AIN457

10 mg/kg

DRUG

Placebo

Matching placebo to AIN457

Sponsors & Collaborators

Principal Investigators

  • NOVARTIS · Novartis investigator site

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-08-31
Completion
2010-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00584740 on ClinicalTrials.gov